Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

Despite our progressive understanding of HIV type-1 (HIV-1) infection and the development of a number of antiretroviral agents to delay the onset of AIDS, there remains a need for agents with improved efficacy and safety. In particular, therapy options for treatment-experienced adult patients have b...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2010-01, Vol.15 (6), p.803-816
Main Authors: TOWNER, William J, CASSETTI, Isabel, DOMINGO, Pere, NIJS, Steven, KAKUDA, Thomas N, VINGERHOETS, Johan, WOODALL, Brian
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
antiretroviral agents
Antiretroviral Therapy, Highly Active
Antiviral agents
Biological and medical sciences
Dose-Response Relationship, Drug
Drug development
Drug resistance
Drug Resistance, Viral
HIV Infections - drug therapy
HIV-1 - drug effects
Human immunodeficiency virus 1
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infection
Infectious diseases
Medical sciences
non-nucleoside reverse transcriptase inhibitors
Pharmacology. Drug treatments
Pyridazines - therapeutic use
Randomized Controlled Trials as Topic
Reverse Transcriptase Inhibitors - pharmacology
Reviews
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite our progressive understanding of HIV type-1 (HIV-1) infection and the development of a number of antiretroviral agents to delay the onset of AIDS, there remains a need for agents with improved efficacy and safety. In particular, therapy options for treatment-experienced adult patients have been limited by the presence of drug-resistant virus, which often leads to a reduced virological response in these patients. The recently approved non-nucleoside reverse transcriptase inhibitor etravirine has demonstrated durable and superior efficacy over placebo and a favourable tolerability profile in HIV-1-infected, treatment-experienced patients, offering a valuable new therapeutic option. This review examines the clinical development and drug profile of etravirine, placing it in the context of other antiretrovirals available for treatment-experienced patients.
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1651